Physicochemical and Pharmacokinetic Profiles of Gadopiclenol
Sign Up to like & getrecommendations! Published in 2019 at "Investigative Radiology"
DOI: 10.1097/rli.0000000000000563
Abstract: Abstract Objectives We aimed to evaluate gadopiclenol, a newly developed extracellular nonspecific macrocyclic gadolinium-based contrast agent (GBCA) having high relaxivity properties, which was designed to increase lesion detection and characterization by magnetic resonance imaging. Methods… read more here.
Keywords: protein binding; relaxivity; profile; gadopiclenol ... See more keywords
Evaluation of Gadopiclenol and P846, 2 High-Relaxivity Macrocyclic Magnetic Resonance Contrast Agents Without Protein Binding, in a Rodent Model of Hepatic Metastases: Potential Solutions for Improved Enhancement at Ultrahigh Field Strength.
Sign Up to like & getrecommendations! Published in 2019 at "Investigative Radiology"
DOI: 10.1097/rli.0000000000000572
Abstract: PURPOSE The aim of this study was to evaluate in vitro and in vivo the enhancement properties of experimental gadolinium (Gd)-based contrast agents (GBCAs) with different molecular weights and hydration numbers (P846 and gadopiclenol) compared… read more here.
Keywords: p846; gadoterate; gadopiclenol; gadopentetate ... See more keywords
Efficacy and Safety of Gadopiclenol for Contrast-Enhanced MRI of the Central Nervous System
Sign Up to like & getrecommendations! Published in 2022 at "Investigative Radiology"
DOI: 10.1097/rli.0000000000000944
Abstract: Objectives Developing new high relaxivity gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) allowing dose reduction while maintaining similar diagnostic efficacy is needed, especially in the context of gadolinium retention in tissues. This study… read more here.
Keywords: mmol; contrast; gadobutrol; gadopiclenol ... See more keywords
Safety of Gadopiclenol After Its First Year of Clinical Use
Sign Up to like & getrecommendations! Published in 2024 at "Investigative Radiology"
DOI: 10.1097/rli.0000000000001144
Abstract: Abstract Gadopiclenol is a novel, macrocyclic high-relaxivity gadolinium-based contrast agent recently approved for use in magnetic resonance imaging of the central nervous system and body organs at a dose of 0.05 mmol/kg body weight. Postmarketing… read more here.
Keywords: first year; use; year clinical; gadopiclenol ... See more keywords
Gadopiclenol Enables Reduced Gadolinium Dose While Maintaining Quality of Pulmonary Arterial Enhancement for Pulmonary MRA
Sign Up to like & getrecommendations! Published in 2025 at "Investigative Radiology"
DOI: 10.1097/rli.0000000000001154
Abstract: Rationale and Objectives: Pulmonary magnetic resonance angiography (MRA) is an imaging method with proven utility for the exclusion of pulmonary embolism and avoids the need for ionizing radiation and iodinated contrast agents. High-relaxivity gadolinium-based contrast… read more here.
Keywords: gadolinium dose; mra; gadopiclenol; pulmonary arterial ... See more keywords
Overall Gadolinium Exposure Within the First 5 Months After Injection of Human Equivalent Doses of Gadopiclenol, Gadoterate, or Gadobutrol in Healthy Rats
Sign Up to like & getrecommendations! Published in 2025 at "Investigative Radiology"
DOI: 10.1097/rli.0000000000001194
Abstract: Introduction: Gadopiclenol is a high relaxivity macrocyclic and nonionic Gadolinium-Based Contrast Agent (GBCA) for central nervous system (CNS) and Body MRI, approved in September 2022 by the Food and Drug Administration and in December 2023… read more here.
Keywords: gadolinium; gadoterate gadobutrol; injection; gadopiclenol ... See more keywords
Contrast-to-Dose Relationship of Gadopiclenol, an MRI Macrocyclic Gadolinium-based Contrast Agent, Compared with Gadoterate, Gadobenate, and Gadobutrol in a Rat Brain Tumor Model.
Sign Up to like & getrecommendations! Published in 2019 at "Radiology"
DOI: 10.1148/radiol.2019182953
Abstract: Background Detection of cerebral lesions at MRI may benefit from a chemically stable and more sensitively detected gadolinium-based contrast agent (GBCA). Gadopiclenol, a macrocyclic GBCA with at least twofold higher relaxivity, is currently undergoing clinical… read more here.
Keywords: gadobenate; gadobutrol; contrast; gadopiclenol ... See more keywords